• Human Sensory Neurons for HSV-1 Latency Research

  2026-10-21

  Oh et al. developed and characterized an inducible human iPSC-derived sensory-neuron system for studying HSV-1 latency and reactivation. The study’s strongest contribution was the convergence of virologic, transcriptional, chromatin, and reactivation evidence rather than any single marker. The model offers a scalable human neuronal context, but its cellular heterogeneity, uncertain maturity, limited genetic diversity, and lack of direct equivalence to human ganglia constrain interpretation. SU 5402 is relevant as an associated receptor-tyrosine-kinase pathway reagent, not as the basis for attributing the study’s central latency findings.

• What HIF-1α Detection Actually Tells You

  2026-10-21

  An anti-HIF-1α signal reports recognized protein in a defined sample context, not hypoxia pathway activity by itself. Understanding the distinction between protein abundance, localization, and downstream transcription helps prevent overinterpretation.

• Adamtsl3, MMP9, and Perineuronal Net Plasticity

  2026-10-20

  A mouse study identifies Adamtsl3 as a parvalbumin-interneuron-associated regulator of perineuronal nets, linking its loss to increased MMP9 activity, reduced Otx2 uptake, oxidative stress, and renewed adult visual-cortex plasticity. SB-3CT is best interpreted here as a pharmacological gelatinase-inhibition probe that supports, but does not by itself prove, an MMP9-dependent mechanism.

• 2X HyperFusion: Claims, Mechanism, and Evidence

  2026-10-19

  A source-limited editorial assessment of the 2X HyperFusion High-Fidelity Master Mix, distinguishing the supplier’s documented enzyme architecture and performance claims from independently established research evidence.

• L-Alanyl-L-Glutamine: Evidence and Scope

  2026-10-18

  L-Alanyl-L-glutamine is identified by APExBIO as a synthetic L-Ala-L-Gln dipeptide with defined chemical and physicochemical specifications. Its gastrointestinal, barrier, antioxidant, inflammatory, and heat-shock claims are documented product assertions rather than findings from an identity-matched research study, so mechanistic and translational conclusions remain limited.

• Seralutinib (GB002): Evidence and Scope

  2026-10-17

  Seralutinib (GB002) is described by APExBIO as an inhalable kinase inhibitor for pulmonary hypertension research. The available product information supports a limited identity and mechanism overview, but provides no named kinase targets, assay readouts, comparative data, effect estimates, or independent study evidence.

• SU 5402: Mechanism, Scope, and Evidence Limits

  2026-10-16

  APExBIO identifies SU 5402, also called SU-5402, as a multi-target receptor tyrosine kinase inhibitor associated with VEGFR2, FGFR1, PDGFRβ, and comparatively weak EGFR inhibition. The available information supports a catalog-level mechanistic model involving receptor phosphorylation, ERK1/2 and STAT3 signaling, and reported cell-cycle or apoptotic phenotypes, but no identity-matched primary paper is available here to establish assay context, reproducibility, effect sizes, or translational relevance.

• What the EGFP sgRNA Product Record Establishes

  2026-10-16

  The APExBIO product record identifies SKU R2997 as three sgRNAs described as targeting EGFP in HeLa cells, with a listed amount of 3 µmol per guide. It does not provide sequences, nuclease context, validation data, or study results, so the record supports a limited identity and conceptual mechanism overview—not claims about editing efficiency, fluorescence changes, specificity, or cellular performance.

• Evacetrapib: What the Product Record Establishes

  2026-10-15

  The APExBIO listing identifies Evacetrapib (LY2484595), SKU A4377, but supplies no product description, mechanism, measurement principle, or study outcomes. Accordingly, the evidence supports a documented identity overview only, not claims about biological activity, performance, or clinical relevance.

• NVP-BGJ398 Phosphate: FGFR Scope and Evidence

  2026-10-15

  NVP-BGJ398 phosphate, also described here as BGJ-398 phosphate, is presented by APExBIO as a selective pan-FGFR1–3 inhibitor with lower potency against FGFR4. The available documentation supports a supplier-attributed mechanism and several proposed research contexts, but no identity-matched research paper is available to independently verify the reported activities, model outcomes, or clinical-development status.

• NVP-BGJ398 Phosphate: Evidence and Scope

  2026-10-14

  NVP-BGJ398 phosphate, also called BGJ-398 phosphate, is described by APExBIO as a selective FGFR1–3 inhibitor that acts by suppressing receptor autophosphorylation and downstream signaling such as ERK1/2. The available evidence here is catalog-level rather than identity-matched primary research, so reported potency, cancer-model activity, and translational relevance should be treated as documented claims with important limits.

• A Bivalent mRNA Vaccine for H5/H7 Avian Influenza

  2026-10-14

  Wei et al. report preclinical evidence that a bivalent mRNA–lipid nanoparticle vaccine targeting H5N1 and H7N9 hemagglutinin induced broad immune responses and protected specific-pathogen-free chickens from several homologous and heterologous virus challenges. The findings are promising but remain bounded by the controlled SPF-chicken model and the study’s limited evidence on durability, field effectiveness, safety, and population-level transmission.

• Recombinant Human FGF-19: Evidence and Scope

  2026-10-13

  The APExBIO product page identifies a tag-free, lyophilized recombinant human FGF-19 protein expressed in E. coli and presents vendor-reported binding, cell-assay, purity, and endotoxin specifications. No matched peer-reviewed paper was provided, so the evidence supports product identity and stated conceptual research scope—not independent confirmation of mechanism, therapeutic activity, or performance across biological systems.

• Lovastatin: Evidence, Mechanism, and Boundaries

  2026-10-13

  Lovastatin is an HMG-CoA reductase inhibitor with broadly reported effects across cholesterol, isoprenoid, proliferation, and inflammatory-cell models. Those findings should not be conflated with the supplied Arabidopsis study, which identifies KNUCKLES as a regulator of auxin distribution and cytokinin activity during floral meristem termination but does not test Lovastatin or the mevalonate pathway.

• Corynoline, Apoptosis, and Evidence Boundaries

  2026-10-12

  A 2025 study reports that corynoline suppressed osteosarcoma models through effects associated with G2/M arrest, mitochondrial apoptosis, and Src/JNK signaling. The findings are mechanistically suggestive but remain preclinical; the supplied summary does not establish a direct molecular target, clinical benefit, or long-term safety.

3684 records 1/246 page Next 12345 下5页 Last page